view4D pharma PLC

4D pharma says cancer conference provides forum for update on lead drug

MRx0518 is an immuno-oncology treatment developed from a single-strain live biotherapeutic

4D pharma plc -

4D pharma plc (LON:DDDD) said it has accepted an invitation to present data at a leading cancer conference.

The company has been given three poster slots at the Society for Immunotherapy of Cancer  (SITC) next month that will focus on clinical trials of its promising single-strain live biotherapeutic, MRx0518.

The first poster will describe initial immune modulation and safety data from the neoadjuvant monotherapy trial in patients awaiting surgery for solid tumours. A neoadjuvant is a drug given as a first step to shrink a tumour before surgery.

Two further posters will provide details of MRx0518 in combination with an existing cancer drug called Keytruda. They were used to treat people who did not respond to immune checkpoint inhibitors.

One poster will provide an additional update on safety and clinical efficacy in patients from the concluded Part A of the study. The other will give information on the ongoing cohort expansion phase of the trial, Part B.

"For the first time, we will be reporting initial immune modulation and safety data from 4D pharma's study of the MRx0518 as a neoadjuvant monotherapy,” 4D’s chief scientific officer, Dr Alex Stevenson said in a statement.   

“This data could be particularly important in developing our understanding of the mechanism of action of MRx0518 in the clinical setting, a key component of maximising its potential as a novel immuno-oncology therapeutic.

“In addition, having reported initial proof-of-concept for the MRx0518 and Keytruda combination study earlier this year, SITC provides the ideal platform to provide an update on progress with this study," he added.

The 35th SITC annual meeting will take place from November 9-14, 2020. The 4D posters can be found in the virtual poster hall from November 11 onwards.

For more information click here.

Quick facts: 4D pharma PLC

Price: 129.865 GBX

Market: LSE
Market Cap: £170.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...


Nano One launches M2CAM and named as one of the TSX Venture top 50 companies

Nano One (CVE: NNO- OTC: NNOMF) CEO Dan Blondal joined Steve Darling from Proactive to share news, Nano One has been named of the TSX Ventures top 50 companies. Blondal shares with Proactive what that means for the company and he also shares with Proactive how their proprietary coated single...

2 days, 15 hours ago

2 min read